Table 1.

The list of 12 open-ended.

1. How long after stroke onset is it indicated to propose treatment with botulinum toxin type A (BoNT-A)?

2. Until when should patients be monitored after the acute event to verify the onset of post-stroke spasticity in order to propose a specific treatment?

3. Until when, after the onset of stroke, is it indicated to propose treatment with BoNT-A in naïve patients?

4. For patients being treated with BoNT-A, how often should a follow-up evaluation and treatment be proposed for more than 12 months from the acute event?

5. For patients treated with BoNT-A, how long after the acute event is it appropriate to continue with follow up and subsequent treatments?

6. Is the goal of treatment with BoNT-A the same or different if the patient is in the subacute or chronic phase?

7. For patients treated with BoNT-A beyond 12 months from the acute event, how to evaluate the possibility of modifying the current treatment schemes (e.g., pattern to be treated, muscles to be treated, dose per muscle and overall dose)?

8. Are the dosages of BoNT-A, according to your experience, in the subacute or chronic phase the same or different?

9. Is the treatment with BoNT-A for the lower limb, in the subacute or chronic phase, also indicated in non-ambulatory patients?

10. Based on your experience, do you think there are differences in treatment frequency between upper limb and lower limb at an early stage?

11. Are there differences in the frequency of treatment between the upper limb and the lower limb in the chronic phase (more than 12 months after the acute event)?

12. Based on your experience, do you think there are differences in the frequency of multilevel treatment in the early phase and in the chronic phase (over 12 months)?